Aurinia Pharmaceuticals reports Q4 EPS $1.53, consensus 22c

Reports Q4 revenue $77.1M, consensus $74.7M. As of December 31, 2025, Aurinia had cash, cash equivalents, restricted cash and investments of $398.0M vs. $358.5M at December 31, 2024. “We are pleased to have delivered strong LUPKYNIS sales growth in 2025,” stated CEO Peter Greenleaf. “We expect 2026 to be an exciting year for Aurinia. We remain focused on increasing LUPKYNIS adoption among lupus nephritis patients and advancing aritinercept, a dual BAFF/APRIL inhibitor, which has the potential to treat a wide range of autoimmune diseases. We have initiated a clinical study of aritinercept in one autoimmune disease and plan to initiate a clinical study in an additional autoimmune disease in the first half of 2026.”